Literature DB >> 1646112

Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules.

S Tamura1, H Funato, Y Hirabayashi, Y Suzuki, T Nagamine, C Aizawa, T Kurata.   

Abstract

Mice that were intranasally immunized with different influenza A virus hemagglutinins (HA), derived from PR8 (H1N1), A/Yamagata (H1N1) or A/Fukuoka (H3N2) virus, together with cholera toxin B subunit as an adjuvant, were examined for protection against PR8 infection; PR8 HA and A/Yamagata HA immunization conferred complete protection, while A/Fukuoka HA immunization failed to confer protection. In parallel with protection, PR8 HA-, A/Yamagata HA-, and A/Fukuoka HA-immunized mice produced a high, a moderate and a low level of PR8 HA-reactive IgA in the respiratory tract, respectively. These IgA antibodies were not only higher in content in the nasal secretions, but also more cross-reactive than IgG. The purified IgA antibodies from respiratory tract washings of PR8 HA-immunized mice, which contained the HA-specific IgA corresponding to the amount detected in the nasal wash, were able to protect mice from PR8 challenge when transferred to the respiratory tract of naive mice. The transfer of IgA from A/Yamagata HA-immunized mice also afforded cross-protection against PR8 infection, whereas the IgA from A/Fukuoka HA-immunized mice failed to provide protection. The ability of transferred IgA to prevent viral infection was dependent on the amount of HA-reactive IgA remaining in the respiratory tract of the host at the time of infection. These experiments directly demonstrate that IgA antibodies to influenza A virus HA by themselves play a pivotal role in defence not only against homologous virus infection, but also against heterologous drift virus infection at the respiratory mucosa, the portal of entry for the viruses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646112     DOI: 10.1002/eji.1830210602

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

Review 3.  Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.

Authors:  Kohtaro Fujihashi; Shintaro Sato; Hiroshi Kiyono
Journal:  Exp Gerontol       Date:  2014-01-16       Impact factor: 4.032

4.  A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging.

Authors:  Hideki Asanuma; Normaiza Binti Zamri; Shinichi Sekine; Yoshiko Fukuyama; Daisuke Tokuhara; Rebekah S Gilbert; Tatsuya Fukuiwa; Keiko Fujihashi; Tetsutaro Sata; Masato Tashiro; Kohtaro Fujihashi
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

5.  Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.

Authors:  Robert Sealy; Richard J Webby; Jeri C Crumpton; Julia L Hurwitz
Journal:  Int Immunol       Date:  2012-11-08       Impact factor: 4.823

6.  Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection.

Authors:  Shigefumi Okamoto; Sumiko Matsuoka; Nobuyuki Takenaka; Ahmad M Haredy; Takeshi Tanimoto; Yasuyuki Gomi; Toyokazu Ishikawa; Takami Akagi; Mitsuru Akashi; Yoshinobu Okuno; Yasuko Mori; Koichi Yamanishi
Journal:  Clin Vaccine Immunol       Date:  2012-05-02

Review 7.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

8.  Elastase-dependent live attenuated swine influenza A viruses are immunogenic and confer protection against swine influenza A virus infection in pigs.

Authors:  Aleksandar Masic; Jayaum S Booth; George K Mutwiri; Lorne A Babiuk; Yan Zhou
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

9.  Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine.

Authors:  Subash C Das; Masato Hatta; Peter R Wilker; Andrzej Myc; Tarek Hamouda; Gabrielle Neumann; James R Baker; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2012-09-16       Impact factor: 3.641

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.